[HTML][HTML] An EUA for Casirivimab and Imdevimab for COVID-19
M Orders - Med Lett Drugs Ther, 2020 - secure.medicalletter.org
M Orders
Med Lett Drugs Ther, 2020•secure.medicalletter.orgRevised 6/17/21: On May 21, 2021, the FDA revised the criteria by which an outpatient with
COVID-19 can be deemed high-risk. On June 3, 2021, the FDA reissued its Emergency Use
Authorization for casirivimab and imdevimab with new dosage and administration
instructions. We have updated our article to reflect these changes.
COVID-19 can be deemed high-risk. On June 3, 2021, the FDA reissued its Emergency Use
Authorization for casirivimab and imdevimab with new dosage and administration
instructions. We have updated our article to reflect these changes.
Revised 6/17/21: On May 21, 2021, the FDA revised the criteria by which an outpatient with COVID-19 can be deemed high-risk. On June 3, 2021, the FDA reissued its Emergency Use Authorization for casirivimab and imdevimab with new dosage and administration instructions. We have updated our article to reflect these changes.
secure.medicalletter.org
